Ig Vena (Human Normal Immunoglobulin)

Human Normal Immunoglobulin delivers a broad spectrum of IgG antibodies that bind to pathogens, neutralize toxins, and interact with immune cell receptors. This passive immunity supplements the patient’s own antibody pool and modulates immune signaling, thereby compensating for deficient or dysfunctional endogenous immunoglobulins.

The dose of Ig Vena is individualized by the prescribing clinician based on the patient’s weight, clinical condition, and response to therapy. Healthcare providers calculate the appropriate infusion volume and rate to achieve the desired immunoglobulin level while monitoring for safety.

The safety of Ig Vena in pregnancy or while breastfeeding has not been definitively established. Clinicians weigh potential benefits against unknown risks and may consider alternative therapies if safer options are available. Patients should discuss their specific situation with a qualified healthcare professional.

To order Ig Vena, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Ig Vena is a pooled human IgG solution comparable to other IVIG products in composition and clinical use. Differences may exist in manufacturing processes, stabilizers, and concentration, which can affect infusion tolerability and storage requirements. Clinicians select a product based on patient tolerance, supply reliability, and institutional preferences.

Ig Vena must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration. Maintain the cold chain during transport and handling to preserve product integrity.

Ig Vena is administered intravenously by a qualified healthcare professional. The infusion is typically given through a peripheral or central line, starting at a low rate and gradually increasing as tolerated. Infusion duration varies with dose and patient response, and vital signs are monitored throughout the procedure.

Serious risks include anaphylactic reactions, thromboembolic events, acute renal failure, aseptic meningitis, and hemolysis. Patients should be closely observed during and after infusion for signs of these events, and immediate medical intervention should be initiated if they occur.

Ig Vena is contraindicated in patients with known severe IgA deficiency who have anti‑IgA antibodies, as they may develop severe anaphylaxis. It should also be avoided in individuals with a history of severe hypersensitivity to immunoglobulin products or any of the excipients used in the formulation.